Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Oral Targeted Anticancer Medication Use Following High-Deductible Health Plan Enrollment.

Created on 10 Nov 2026

Authors

Michael R Eber, Rebecca Costa, Stephanie Argetsinger, Mahnum Shahzad, Fang Zhang, J Frank Wharam, Dennis Ross-Degnan, Anita K Wagner

Published in

The American journal of managed care. Volume 32. Issue 10. Pages 545-547.

Abstract

Out-of-pocket (OOP) spending obligations associated with high-deductible health plans (HDHPs) may reduce health care utilization, but evidence on how enrollment in HDHPs affects use of oral targeted anticancer medications (OTAMs) is limited. We used difference-in-differences regression analyses to examine the associations among employer-mandated enrollment in an HDHP, OOP spending, and use of OTAMs in a commercially insured population between 2007 and 2021. Among users of OTAMs, we found that HDHP enrollment may have increased OOP spending but was not associated with reductions in the use of these anticancer agents over a 1-year follow-up period. Research should continue to examine the links among patient cost sharing, cancer care utilization, and spending trade-offs, particularly for low-income patients with cancer.

PMID:
43007287
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement